阿司匹林162毫克与81毫克用于高危肥胖个体子痫前期预防:一项比较有效性开放标签随机试验(ASPREO)
该随机试验纳入孕12-20周、体重指数≥30 kg/m²且至少有一项高危因素的孕妇,比较每日162毫克与81毫克阿司匹林预防子痫前期伴严重特征的效果。162毫克组主要结局发生率35%,81毫克组40%,贝叶斯分析显示162毫克组降低主要结局的概率为78%,相对风险0.88(95%可信区间0.64-1.22)。作者认为该试验支持开展更大规模的多中心试验。
要点
- 在高危肥胖孕妇中,162毫克阿司匹林较81毫克降低子痫前期伴严重特征的概率为78%。
- 162毫克组主要结局发生率35%(37/107),81毫克组40%(41/102),相对风险0.88(95%可信区间0.64-1.22)。
- 两组早产、小于胎龄儿、胎盘早剥、产后出血及药物副作用发生率相似。
核心结论
- 在高危肥胖个体中,与81毫克阿司匹林相比,162毫克阿司匹林降低子痫前期伴严重特征发生率的获益概率为78%,最佳估计为降低12%。
- 该试验支持开展更大规模的多中心试验。
研究设计与样本
- 研究为比较有效性开放标签随机试验,于2019年5月至2022年11月进行。
- 纳入孕12-20周、体重指数≥30 kg/m²且至少有一项高危因素(既往子痫前期病史、本次妊娠至少I期高血压、孕前糖尿病或孕20周前诊断的妊娠期糖尿病)的个体,随机接受每日162毫克或81毫克阿司匹林直至分娩,参与者对治疗分配未设盲。
- 排除标准包括多胎妊娠、已知重大胎儿异常、癫痫发作性疾病、基线蛋白尿、因其他指征服用阿司匹林或阿司匹林禁忌。
- 采用预先计划的贝叶斯分析,样本量220例,以估计获益或伤害的后验概率。
- 343例中约220例(64.1%)被随机分配,209/220例(95%)有主要结局数据。
主要发现
- 162毫克阿司匹林组主要结局发生于37/107例(35%),81毫克阿司匹林组发生于41/102例(40%)(后验相对风险0.88,95%可信区间0.64-1.22)。
- 贝叶斯分析表明,162毫克阿司匹林较81毫克阿司匹林降低主要结局的概率为78%。
- 因子痫前期指征早产率(21% vs 21%)、小于胎龄儿(6.5% vs 2.9%)、胎盘早剥(2.8% vs 3.0%)及产后出血(10.0% vs 8.8%)两组相似。
- 药物不良反应两组也相似。
- 入组时中位孕周在162毫克组为15.9周,在81毫克组为15.6周;16周前入组者在162毫克组为55/110例,在81毫克组为58/110例。
关键数值与推荐
- 美国主要医学会推荐每日81毫克阿司匹林用于有风险女性的子痫前期预防,而英国NICE指南推荐剂量高达150毫克。
- 近期数据提示在肥胖人群中,剂量不足或阿司匹林抵抗可能影响当前推荐剂量阿司匹林的疗效。
临床怎么用
- 作者认为该试验支持开展更大规模的多中心试验。
局限性
- 该试验支持开展更大规模的多中心试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the United States, leading medical societies recommend 81 mg of aspirin daily for the prevention of preeclampsia in women at risk, whereas the NICE guidelines in the United Kingdom recommend a dose as high as 150 mg of aspirin. Recent data also suggest that in the obese population, inadequate dosing or aspirin resistance may impact the efficacy of aspirin at the currently recommended doses. OBJECTIVE: We evaluated whether daily administration of 162 mg aspirin would be more effective compared with 81 mg in decreasing the rate of preeclampsia with severe features in high-risk obese pregnant individuals. STUDY DESIGN: We performed a randomized trial between May 2019 and November 2022. Individuals at 12-20 weeks of gestational age with a body mass index ≥30 kg/m2 at the time of enrollment and at least 1 of 3 high-risk factors: history of preeclampsia in a prior pregnancy, at least stage I hypertension documented in the index pregnancy, pregestational diabetes or gestational diabetes diagnosed before 20 weeks of gestational age were randomized to either 162 mg or 81 mg of aspirin daily till delivery, participants were not blinded to treatment allocation. Exclusion criteria were multifetal gestation, known major fetal anomalies, seizure disorder, baseline proteinuria, on aspirin because of other indications, or contraindication to aspirin. The primary outcome was preeclampsia with severe features (preeclampsia or superimposed preeclampsia with severe features; eclampsia; or hemolysis, elevated liver enzymes, low platelet count syndrome). Secondary outcomes included rates of preterm birth because of preeclampsia, small for gestational age, postpartum hemorrhage, abruption, and medication side effects. A sample size of 220 was needed using a preplanned Bayesian analysis of the primary outcome to estimate the posterior probability of benefit or harm with a neutral informative prior. RESULTS: Approximately 220/343 (64.1%) individuals were randomized. The primary outcome was available for 209/220 (95%) individuals. Baseline characteristics were similar between groups, with the median gestational age at enrollment being 15.9 weeks in the 162 mg aspirin group and 15.6 weeks in the 81 mg aspirin group. Enrollment before 16 weeks occurred in 55 of 110 of those assigned to 162 mg and 58 of 110 of those assigned to 81 mg of aspirin. The primary outcome occurred in 37 of 107 individuals (35%) in the 162 mg aspirin group and 41 of 102 individuals (40%) in the 81 mg aspirin group (posterior relative risk, 0.88; 95% credible interval, 0.64-1.22). Bayesian analysis indicated a 78% probability of a reduction in the primary outcome with 162 mg aspirin compared with 81 mg aspirin dose. Rates of indicated preterm birth because of preeclampsia (21% vs 21%), small for gestational age (6.5% vs 2.9%), abruption (2.8% vs 3.0%), and postpartum hemorrhage (10.0% vs 8.8%) were similar between groups. Medication adverse effects were also similar. CONCLUSION: Among high-risk obese individuals, there was a 78% probability of benefit that 162 mg aspirin compared with 81 mg will decrease the rate of preeclampsia with severe features. With the best estimate of a 12% reduction when using 162 mg of aspirin compared with 81 mg of aspirin in this population. This trial supports doing a larger multicenter trial.
引用
- Amro FH, Blackwell SC, Pedroza C, et al. Aspirin 162 mg vs 81 mg for preeclampsia prophylaxis in high-risk obese individuals: a comparative effectiveness open-label randomized trial (ASPREO). Am J Obstet Gynecol. 2024. PMID: 38977068. doi:10.1016/j.ajog.2024.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。